Literature DB >> 16092076

Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting.

Tomaso Scaravilli1, Eduardo Tolosa, Isidre Ferrer.   

Abstract

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are both sporadic disorders with tau pathology. Criteria have been defined that in most instances allow for adequate diagnosis of the two disorders both clinically and neuropathologically; however, overlap is not uncommon. For example, patients with PSP may present with severe unilateral apraxia and supranuclear gaze palsy can occur in CBD. Pathological overlap also occurs and pathologically "mixed" cases are encountered. Common to both these two tauopathies is that isoforms of four-repeat tau due to splicing of exon 10 define the tau filamentous aggregates. This is in contrast to other tau disorders such as Pick's with three-repeat tau aggregates. Additional evidence for a causal link between PSP and CBD is the finding that both disorders are homozygous for the H1 tau haplotype. Furthermore, in some families with parkinsonism linked to defined mutations of the tau gene (FTDP-17), involved relatives have presented with PSP whereas others with the CBD phenotype. Although PSP and CBD frequently can be clearly separated clinically and pathologically, the degree of clinicopathological and genetic overlap is important and suggests that they represent different phenotypes of the same disorder, with differences occurring perhaps in relation to different genetic background. That PSP and CBD are distinct nosological entities occurring in patients with similar genetic predisposition cannot be ruled out. Copyright 2005 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16092076     DOI: 10.1002/mds.20536

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  17 in total

1.  Potential usefulness of signal intensity of cerebral gyri on quantitative susceptibility mapping for discriminating corticobasal degeneration from progressive supranuclear palsy and Parkinson's disease.

Authors:  Mari Miyata; Shingo Kakeda; Yasuko Toyoshima; Satoru Ide; Kazumasa Okada; Hiroaki Adachi; Yi Wang; Yukunori Korogi
Journal:  Neuroradiology       Date:  2019-07-02       Impact factor: 2.804

Review 2.  The corticobasal syndrome-Alzheimer's disease conundrum.

Authors:  Anhar Hassan; Jennifer L Whitwell; Keith A Josephs
Journal:  Expert Rev Neurother       Date:  2011-11       Impact factor: 4.618

3.  Interhemispheric inhibition in different phenotypes of progressive supranuclear palsy.

Authors:  M Wittstock; I Pohley; U Walter; A Grossmann; R Benecke; A Wolters
Journal:  J Neural Transm (Vienna)       Date:  2012-08-15       Impact factor: 3.575

4.  Sound naming in neurodegenerative disease.

Authors:  Maggie L Chow; Simona M Brambati; Maria Luisa Gorno-Tempini; Bruce L Miller; Julene K Johnson
Journal:  Brain Cogn       Date:  2010-01-20       Impact factor: 2.310

5.  Glycolitic enzymes are targets of oxidation in aged human frontal cortex and oxidative damage of these proteins is increased in progressive supranuclear palsy.

Authors:  A Martínez; E Dalfó; G Muntané; I Ferrer
Journal:  J Neural Transm (Vienna)       Date:  2007-08-21       Impact factor: 3.575

6.  Pathology-Proven Corticobasal Degeneration Presenting as Richardson's Syndrome.

Authors:  Ece Bayram; Dennis W Dickson; Stephen G Reich; Irene Litvan
Journal:  Mov Disord Clin Pract       Date:  2020-02-14

7.  Phenotypic variation of autosomal-dominant corticobasal degeneration.

Authors:  Hans H Jung; Juliane Bremer; Johannes Streffer; Kanwar Virdee; Maria Grazia Spillantini; R Anthony Crowther; Peter Brugger; Christine Van Broeckhoven; Adriano Aguzzi; Markus Tolnay
Journal:  Eur Neurol       Date:  2012-01-18       Impact factor: 1.710

8.  Clinico-pathological correlations of the most common neurodegenerative dementias.

Authors:  Ricardo Taipa; João Pinho; Manuel Melo-Pires
Journal:  Front Neurol       Date:  2012-05-01       Impact factor: 4.003

9.  The feasibility of white matter volume reduction analysis using SPM8 plus DARTEL for the diagnosis of patients with clinically diagnosed corticobasal syndrome and Richardson's syndrome.

Authors:  Keita Sakurai; Etsuko Imabayashi; Aya M Tokumaru; Shin Hasebe; Shigeo Murayama; Satoru Morimoto; Kazutomi Kanemaru; Masaki Takao; Yuta Shibamoto; Noriyuki Matsukawa
Journal:  Neuroimage Clin       Date:  2014-02-27       Impact factor: 4.881

10.  Comprehensive mRNA expression profiling distinguishes tauopathies and identifies shared molecular pathways.

Authors:  Iraad F Bronner; Zoltán Bochdanovits; Patrizia Rizzu; Wouter Kamphorst; Rivka Ravid; John C van Swieten; Peter Heutink
Journal:  PLoS One       Date:  2009-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.